Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Diabetes

Date Submitted: Jun 15, 2022
Date Accepted: Sep 1, 2022

The final, peer-reviewed published version of this preprint can be found here:

Improved Glycemia and Quality of Life Among Loop Users: Analysis of Real-world Data From a Single Center

Morrison AE, Chong K, Lai V, Farnsworth K, Senior PA, Lam A

Improved Glycemia and Quality of Life Among Loop Users: Analysis of Real-world Data From a Single Center

JMIR Diabetes 2022;7(4):e40326

DOI: 10.2196/40326

PMID: 36279156

PMCID: 9641512

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Improved Glycemia and Quality of Life Among Loop users – Analysis of Real-World Data from a Single Centre

  • Amy E. Morrison; 
  • Kimberley Chong; 
  • Valerie Lai; 
  • Kate Farnsworth; 
  • Peter A. Senior; 
  • Anna Lam

ABSTRACT

Background:

Despite being an unapproved method of insulin delivery, increasing numbers of people with type 1 diabetes (T1D) worldwide are choosing to use Loop, a Do-It-Yourself Automated Insulin Delivery system.

Objective:

We aimed to assess glycemic outcomes, safety and the perceived impact on quality of life (QOL), in a local Edmonton cohort of known Loop users.

Methods:

An observational study of adults with T1D using Loop was performed. Assessment of glycemic; HbA1c and time in range (TIR), and safety outcomes; hospital admissions and time below range (TBR), compared six months of Loop with the user’s prior regulatory approved insulin delivery method. QOL outcomes were assessed using INSPIRE, Diabetes Impact and Device Satisfaction (DIDS) measures (with maximum scores of 100, 10 and 10), and semi-structured interviews.

Results:

24 adults with T1D, 66.7% female, median (IQR) age 33 (28-45), duration of diabetes 22 years (17-32), with duration of Loop 18 months (12-25). With Loop, median (IQR) HbA1c 7.1% (6.5-7.5), 54mmol/mol (48-58) and TIR 76.5% (64.6-81.9); a significant improvement from prior therapy (p=0.001 and p=0.005), with a non-significant reduction in time 3.0-3.9mmol/L (p=0.17) and <3mmol/L (p=0.53). Two episodes of DKA and no severe hypoglycemia occurred in a total of 470 months Loop use. Positive QOL impact was explored in qualitative analysis and additionally demonstrated through median (IQR) INSPIRE 86 (79-95), DI 2.8 (2.1-3.9) and DS 9 (8.2-9.4).

Conclusions:

This local cohort of people with T1D, demonstrate a beneficial effect of Loop use on both glycemic control and QOL, with no safety concerns highlighted. Clinical Trial: N/A


 Citation

Please cite as:

Morrison AE, Chong K, Lai V, Farnsworth K, Senior PA, Lam A

Improved Glycemia and Quality of Life Among Loop Users: Analysis of Real-world Data From a Single Center

JMIR Diabetes 2022;7(4):e40326

DOI: 10.2196/40326

PMID: 36279156

PMCID: 9641512

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.